NCT03799003: A Study of ASP1951 in Subjects With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with leptomeningeal disease and/or symptomatic, unstable, untreated central nervous system (CNS) metastases – see trial for details; Patients who have received prior treatment with an anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody

Comments are closed.

Up ↑